Global CRISPER-associated Nucleases 麻豆原创 Research Report 2024

Publication ID:

PB502250516

Publication Date:

February 22, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

A programmable tools used for CRISPER (clusters of regularly interspaced short palindromic repeats), which could mediate targeted DNA or RNA cleavage. These sepecific endonuclease drives targeted gene disruption through nonhomologous end joining (NHEJ) or precise gene editing through template-dependent homology-directed repair (HDR).
The global CRISPER-associated Nucleases market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for CRISPER-associated Nucleases is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for CRISPER-associated Nucleases is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of CRISPER-associated Nucleases include The Odin, Origene, Amsbio, Thermo Fisher Scientific, Merck, Boai Nky Medical Holdings Ltd, Biocompare, BioLabs, Inc. and Inscripta, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for CRISPER-associated Nucleases, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding CRISPER-associated Nucleases.
Report Scope
The CRISPER-associated Nucleases market size, estimations, and forecasts are provided in terms of sales volume (Kg) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global CRISPER-associated Nucleases market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the CRISPER-associated Nucleases manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
The Odin
Origene
Amsbio
Thermo Fisher Scientific
Merck
Boai Nky Medical Holdings Ltd
Biocompare
BioLabs, Inc.
Inscripta
Sherlock Biosciences
Editas
CRISPR Therapeutics
Synthego
Addgene
IDT (Integrated DNA Technologies)
Horizon Discovery
ToolGen
GenScript
New England Biolabs (NEB)
Segment by Type
CRISPER-associated Protein 9 (Cas 9)
Cpf 1
CRISPER-associated Protein 13 (Cas 13)
Segment by Application
DNA Editing
RNA Editing
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of CRISPER-associated Nucleases manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of CRISPER-associated Nucleases in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 CRISPER-associated Nucleases 麻豆原创 Overview
1.1 Product Overview and Scope of CRISPER-associated Nucleases
1.2 CRISPER-associated Nucleases Segment by Type
1.2.1 Global CRISPER-associated Nucleases 麻豆原创 Value Comparison by Type (2024-2030)
1.2.2 CRISPER-associated Protein 9 (Cas 9)
1.2.3 Cpf 1
1.2.4 CRISPER-associated Protein 13 (Cas 13)
1.3 CRISPER-associated Nucleases Segment by Application
1.3.1 Global CRISPER-associated Nucleases 麻豆原创 Value by Application: (2024-2030)
1.3.2 DNA Editing
1.3.3 RNA Editing
1.4 Global CRISPER-associated Nucleases 麻豆原创 Size Estimates and Forecasts
1.4.1 Global CRISPER-associated Nucleases Revenue 2019-2030
1.4.2 Global CRISPER-associated Nucleases Sales 2019-2030
1.4.3 Global CRISPER-associated Nucleases 麻豆原创 Average Price (2019-2030)
1.5 Assumptions and Limitations
2 CRISPER-associated Nucleases 麻豆原创 Competition by Manufacturers
2.1 Global CRISPER-associated Nucleases Sales 麻豆原创 Share by Manufacturers (2019-2024)
2.2 Global CRISPER-associated Nucleases Revenue 麻豆原创 Share by Manufacturers (2019-2024)
2.3 Global CRISPER-associated Nucleases Average Price by Manufacturers (2019-2024)
2.4 Global CRISPER-associated Nucleases Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of CRISPER-associated Nucleases, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of CRISPER-associated Nucleases, Product Type & Application
2.7 CRISPER-associated Nucleases 麻豆原创 Competitive Situation and Trends
2.7.1 CRISPER-associated Nucleases 麻豆原创 Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest CRISPER-associated Nucleases Players 麻豆原创 Share by Revenue
2.7.3 Global CRISPER-associated Nucleases 麻豆原创 Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 CRISPER-associated Nucleases Retrospective 麻豆原创 Scenario by Region
3.1 Global CRISPER-associated Nucleases 麻豆原创 Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global CRISPER-associated Nucleases Global CRISPER-associated Nucleases Sales by Region: 2019-2030
3.2.1 Global CRISPER-associated Nucleases Sales by Region: 2019-2024
3.2.2 Global CRISPER-associated Nucleases Sales by Region: 2025-2030
3.3 Global CRISPER-associated Nucleases Global CRISPER-associated Nucleases Revenue by Region: 2019-2030
3.3.1 Global CRISPER-associated Nucleases Revenue by Region: 2019-2024
3.3.2 Global CRISPER-associated Nucleases Revenue by Region: 2025-2030
3.4 North America CRISPER-associated Nucleases 麻豆原创 Facts & Figures by Country
3.4.1 North America CRISPER-associated Nucleases 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America CRISPER-associated Nucleases Sales by Country (2019-2030)
3.4.3 North America CRISPER-associated Nucleases Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe CRISPER-associated Nucleases 麻豆原创 Facts & Figures by Country
3.5.1 Europe CRISPER-associated Nucleases 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe CRISPER-associated Nucleases Sales by Country (2019-2030)
3.5.3 Europe CRISPER-associated Nucleases Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific CRISPER-associated Nucleases 麻豆原创 Facts & Figures by Country
3.6.1 Asia Pacific CRISPER-associated Nucleases 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific CRISPER-associated Nucleases Sales by Country (2019-2030)
3.6.3 Asia Pacific CRISPER-associated Nucleases Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America CRISPER-associated Nucleases 麻豆原创 Facts & Figures by Country
3.7.1 Latin America CRISPER-associated Nucleases 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America CRISPER-associated Nucleases Sales by Country (2019-2030)
3.7.3 Latin America CRISPER-associated Nucleases Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa CRISPER-associated Nucleases 麻豆原创 Facts & Figures by Country
3.8.1 Middle East and Africa CRISPER-associated Nucleases 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa CRISPER-associated Nucleases Sales by Country (2019-2030)
3.8.3 Middle East and Africa CRISPER-associated Nucleases Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global CRISPER-associated Nucleases Sales by Type (2019-2030)
4.1.1 Global CRISPER-associated Nucleases Sales by Type (2019-2024)
4.1.2 Global CRISPER-associated Nucleases Sales by Type (2025-2030)
4.1.3 Global CRISPER-associated Nucleases Sales 麻豆原创 Share by Type (2019-2030)
4.2 Global CRISPER-associated Nucleases Revenue by Type (2019-2030)
4.2.1 Global CRISPER-associated Nucleases Revenue by Type (2019-2024)
4.2.2 Global CRISPER-associated Nucleases Revenue by Type (2025-2030)
4.2.3 Global CRISPER-associated Nucleases Revenue 麻豆原创 Share by Type (2019-2030)
4.3 Global CRISPER-associated Nucleases Price by Type (2019-2030)
5 Segment by Application
5.1 Global CRISPER-associated Nucleases Sales by Application (2019-2030)
5.1.1 Global CRISPER-associated Nucleases Sales by Application (2019-2024)
5.1.2 Global CRISPER-associated Nucleases Sales by Application (2025-2030)
5.1.3 Global CRISPER-associated Nucleases Sales 麻豆原创 Share by Application (2019-2030)
5.2 Global CRISPER-associated Nucleases Revenue by Application (2019-2030)
5.2.1 Global CRISPER-associated Nucleases Revenue by Application (2019-2024)
5.2.2 Global CRISPER-associated Nucleases Revenue by Application (2025-2030)
5.2.3 Global CRISPER-associated Nucleases Revenue 麻豆原创 Share by Application (2019-2030)
5.3 Global CRISPER-associated Nucleases Price by Application (2019-2030)
6 Key Companies Profiled
6.1 The Odin
6.1.1 The Odin Corporation Information
6.1.2 The Odin Description and Business Overview
6.1.3 The Odin CRISPER-associated Nucleases Sales, Revenue and Gross Margin (2019-2024)
6.1.4 The Odin CRISPER-associated Nucleases Product Portfolio
6.1.5 The Odin Recent Developments/Updates
6.2 Origene
6.2.1 Origene Corporation Information
6.2.2 Origene Description and Business Overview
6.2.3 Origene CRISPER-associated Nucleases Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Origene CRISPER-associated Nucleases Product Portfolio
6.2.5 Origene Recent Developments/Updates
6.3 Amsbio
6.3.1 Amsbio Corporation Information
6.3.2 Amsbio Description and Business Overview
6.3.3 Amsbio CRISPER-associated Nucleases Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Amsbio CRISPER-associated Nucleases Product Portfolio
6.3.5 Amsbio Recent Developments/Updates
6.4 Thermo Fisher Scientific
6.4.1 Thermo Fisher Scientific Corporation Information
6.4.2 Thermo Fisher Scientific Description and Business Overview
6.4.3 Thermo Fisher Scientific CRISPER-associated Nucleases Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Thermo Fisher Scientific CRISPER-associated Nucleases Product Portfolio
6.4.5 Thermo Fisher Scientific Recent Developments/Updates
6.5 Merck
6.5.1 Merck Corporation Information
6.5.2 Merck Description and Business Overview
6.5.3 Merck CRISPER-associated Nucleases Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Merck CRISPER-associated Nucleases Product Portfolio
6.5.5 Merck Recent Developments/Updates
6.6 Boai Nky Medical Holdings Ltd
6.6.1 Boai Nky Medical Holdings Ltd Corporation Information
6.6.2 Boai Nky Medical Holdings Ltd Description and Business Overview
6.6.3 Boai Nky Medical Holdings Ltd CRISPER-associated Nucleases Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Boai Nky Medical Holdings Ltd CRISPER-associated Nucleases Product Portfolio
6.6.5 Boai Nky Medical Holdings Ltd Recent Developments/Updates
6.7 Biocompare
6.6.1 Biocompare Corporation Information
6.6.2 Biocompare Description and Business Overview
6.6.3 Biocompare CRISPER-associated Nucleases Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Biocompare CRISPER-associated Nucleases Product Portfolio
6.7.5 Biocompare Recent Developments/Updates
6.8 BioLabs, Inc.
6.8.1 BioLabs, Inc. Corporation Information
6.8.2 BioLabs, Inc. Description and Business Overview
6.8.3 BioLabs, Inc. CRISPER-associated Nucleases Sales, Revenue and Gross Margin (2019-2024)
6.8.4 BioLabs, Inc. CRISPER-associated Nucleases Product Portfolio
6.8.5 BioLabs, Inc. Recent Developments/Updates
6.9 Inscripta
6.9.1 Inscripta Corporation Information
6.9.2 Inscripta Description and Business Overview
6.9.3 Inscripta CRISPER-associated Nucleases Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Inscripta CRISPER-associated Nucleases Product Portfolio
6.9.5 Inscripta Recent Developments/Updates
6.10 Sherlock Biosciences
6.10.1 Sherlock Biosciences Corporation Information
6.10.2 Sherlock Biosciences Description and Business Overview
6.10.3 Sherlock Biosciences CRISPER-associated Nucleases Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Sherlock Biosciences CRISPER-associated Nucleases Product Portfolio
6.10.5 Sherlock Biosciences Recent Developments/Updates
6.11 Editas
6.11.1 Editas Corporation Information
6.11.2 Editas CRISPER-associated Nucleases Description and Business Overview
6.11.3 Editas CRISPER-associated Nucleases Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Editas CRISPER-associated Nucleases Product Portfolio
6.11.5 Editas Recent Developments/Updates
6.12 CRISPR Therapeutics
6.12.1 CRISPR Therapeutics Corporation Information
6.12.2 CRISPR Therapeutics CRISPER-associated Nucleases Description and Business Overview
6.12.3 CRISPR Therapeutics CRISPER-associated Nucleases Sales, Revenue and Gross Margin (2019-2024)
6.12.4 CRISPR Therapeutics CRISPER-associated Nucleases Product Portfolio
6.12.5 CRISPR Therapeutics Recent Developments/Updates
6.13 Synthego
6.13.1 Synthego Corporation Information
6.13.2 Synthego CRISPER-associated Nucleases Description and Business Overview
6.13.3 Synthego CRISPER-associated Nucleases Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Synthego CRISPER-associated Nucleases Product Portfolio
6.13.5 Synthego Recent Developments/Updates
6.14 Addgene
6.14.1 Addgene Corporation Information
6.14.2 Addgene CRISPER-associated Nucleases Description and Business Overview
6.14.3 Addgene CRISPER-associated Nucleases Sales, Revenue and Gross Margin (2019-2024)
6.14.4 Addgene CRISPER-associated Nucleases Product Portfolio
6.14.5 Addgene Recent Developments/Updates
6.15 IDT (Integrated DNA Technologies)
6.15.1 IDT (Integrated DNA Technologies) Corporation Information
6.15.2 IDT (Integrated DNA Technologies) CRISPER-associated Nucleases Description and Business Overview
6.15.3 IDT (Integrated DNA Technologies) CRISPER-associated Nucleases Sales, Revenue and Gross Margin (2019-2024)
6.15.4 IDT (Integrated DNA Technologies) CRISPER-associated Nucleases Product Portfolio
6.15.5 IDT (Integrated DNA Technologies) Recent Developments/Updates
6.16 Horizon Discovery
6.16.1 Horizon Discovery Corporation Information
6.16.2 Horizon Discovery CRISPER-associated Nucleases Description and Business Overview
6.16.3 Horizon Discovery CRISPER-associated Nucleases Sales, Revenue and Gross Margin (2019-2024)
6.16.4 Horizon Discovery CRISPER-associated Nucleases Product Portfolio
6.16.5 Horizon Discovery Recent Developments/Updates
6.17 ToolGen
6.17.1 ToolGen Corporation Information
6.17.2 ToolGen CRISPER-associated Nucleases Description and Business Overview
6.17.3 ToolGen CRISPER-associated Nucleases Sales, Revenue and Gross Margin (2019-2024)
6.17.4 ToolGen CRISPER-associated Nucleases Product Portfolio
6.17.5 ToolGen Recent Developments/Updates
6.18 GenScript
6.18.1 GenScript Corporation Information
6.18.2 GenScript CRISPER-associated Nucleases Description and Business Overview
6.18.3 GenScript CRISPER-associated Nucleases Sales, Revenue and Gross Margin (2019-2024)
6.18.4 GenScript CRISPER-associated Nucleases Product Portfolio
6.18.5 GenScript Recent Developments/Updates
6.19 New England Biolabs (NEB)
6.19.1 New England Biolabs (NEB) Corporation Information
6.19.2 New England Biolabs (NEB) CRISPER-associated Nucleases Description and Business Overview
6.19.3 New England Biolabs (NEB) CRISPER-associated Nucleases Sales, Revenue and Gross Margin (2019-2024)
6.19.4 New England Biolabs (NEB) CRISPER-associated Nucleases Product Portfolio
6.19.5 New England Biolabs (NEB) Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 CRISPER-associated Nucleases Industry Chain Analysis
7.2 CRISPER-associated Nucleases Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 CRISPER-associated Nucleases Production Mode & Process
7.4 CRISPER-associated Nucleases Sales and 麻豆原创ing
7.4.1 CRISPER-associated Nucleases Sales Channels
7.4.2 CRISPER-associated Nucleases Distributors
7.5 CRISPER-associated Nucleases Customers
8 CRISPER-associated Nucleases 麻豆原创 Dynamics
8.1 CRISPER-associated Nucleases Industry Trends
8.2 CRISPER-associated Nucleases 麻豆原创 Drivers
8.3 CRISPER-associated Nucleases 麻豆原创 Challenges
8.4 CRISPER-associated Nucleases 麻豆原创 Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 麻豆原创 Size Estimation
10.1.3 麻豆原创 Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

The Odin
Origene
Amsbio
Thermo Fisher Scientific
Merck
Boai Nky Medical Holdings Ltd
Biocompare
BioLabs, Inc.
Inscripta
Sherlock Biosciences
Editas
CRISPR Therapeutics
Synthego
Addgene
IDT (Integrated DNA Technologies)
Horizon Discovery
ToolGen
GenScript
New England Biolabs (NEB)

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.